BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer Meeting Abstract
| Authors: | Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Gollerkeri, F.; Maharry, K.; Loupakis, F.; Hong, Y.; Steeghs, F.; Guren, T.; Arkenau, H.; Alfonso, P. G.; Sandor, V.; Christy-Bittel, J.; Anderson, L.; Tabernero, J. |
| Abstract Title: | BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer |
| Meeting Title: | ESMO 21st World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Jul 3-6 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-07-01 |
| Start Page: | mdz183.004 |
| Language: | English |
| ACCESSION: | WOS:000475860200450 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz183.004 |
| Notes: | Meeting Abstract: LBA-006 -- Appears on page iv154 of the abstract book -- Source: Wos |
